G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.30 USD
-0.01 (-0.30%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.31 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 101 - 120 ( 351 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
New Data Support Cosela Potential in Reducing Myelosuppression Due to Chemotherapy in Patients with ES-SCLC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q21 Results; Cosela Sales Expected to Ramp Up in 2H22; Several Data Readouts in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q21: Sequential Revenue Growth. In-House Sales Team in Effect. PT $35.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
General Conference 2022: Face To Face. Synopsis of Select Companies
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Early Data from Three Trials Slated During Second Half of This Year
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Additional Hires Announced for Cosela Sales Force Amid Transition Away From Co-Promotion
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Cosela Ringing in ''22 By Getting Rid of Ringers
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department